Relief Therapeutics

Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva.[1] The company was founded in 2013 and currently holds a patent for RLF-100, a synthetic form of a natural peptide that protects the lung. It was incorporated as Relief Therapeutics Holdings AG (RFLB.S) and listed on the SIX Swiss Exchange in 2016.[2]

Relief Therapeutics
TypePublic
IndustryBiopharmaceutical
Founded2013
HeadquartersGeneva, Switzerland
Key people
Raghuram Selvaraju
(Chairman)
Jack Weinstein
(Chief Financial Officer)
ProductsRLF-100
Websiterelieftherapeutics.com

In the wake of the COVID-19 pandemic, scientists at Relief conducted initial studies into the efficacy of RLF-100 in treating severe COVID-19 patients. In June 2020, the U.S. Food and Drug Administration granted fast-track designation to RLF-100 for treatment of respiratory distress in COVID-19.[3][4] In September 2020, Relief partnered with US-Israeli firm NeuroRX, who submitted a request for an Emergency Use Authorization to the US FDA for its use in patients in intensive care. [5][6]

Acquisitions

References
  1. "Company, About Us". Relief Therapeutics. Retrieved January 21, 2021.
  2. "Share Details - Relief Therapeutics". SIX Swiss Exchange. Retrieved January 21, 2021.
  3. "Critically ill COVID-19 patients make quick recovery with treatment RLF-100". New York Post. 2 August 2020. Retrieved 3 August 2020.
  4. "Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure (COVID-AIV)". US National Library of Medicine. March 17, 2020. Retrieved January 21, 2021.
  5. NeuroRx. "NeuroRx submits request for Emergency Use Authorization for RLF-100™ (aviptadil) in the treatment of patients with Critical COVID-19 and Respiratory Failure who have exhausted approved therapy". www.prnewswire.com. Retrieved 2020-09-24.
  6. "Inhaled Aviptadil for the Prevention of COVID-19 Related ARDS". US National Library of Medicine. September 2, 2020. Retrieved January 21, 2021.
  7. "Relief Therapeutics to acquire FirstString Research". thepharmaletter.com. July 29, 2016. Retrieved January 21, 2021.
  8. "Relief Therapeutics takes over AdVita". Finanz und Wirtschaft. January 20, 2020. Retrieved January 21, 2021.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.